Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give Urogen Pharma a “Moderate Buy” consensus rating: Seven analysts rate the stock a buy, one a strong buy, one a hold and one a sell. The average 12-month price target is $50.38, above the reported $46.86 share price.
• Urogen’s shares have risen substantially, trading near their 52-week high of $50.81, with a 50-day moving average of $40.51 and a 200-day average of $29.07. However, the company’s latest quarterly EPS loss of $0.28 was slightly worse than analyst expectations, despite revenue of $72.46 million exceeding forecasts.
• Institutional ownership is high at 91.29%. Major investors including BlackRock, Jefferies and Soleus Capital recently established or expanded positions, while insiders sold 25,222 shares worth approximately $892,661 over the past three months.

Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $50.3750.

URGN has been the topic of several recent research reports. LADENBURG THALM/SH SH initiated coverage on Urogen Pharma in a research report on Monday, May 11th. They issued a "buy" rating and a $43.00 price target on the stock. Guggenheim upped their price objective on Urogen Pharma from $42.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Oppenheimer increased their price objective on Urogen Pharma from $40.00 to $50.00 and gave the stock an "outperform" rating in a research report on Thursday, July 16th. UBS Group reiterated a "buy" rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $44.00 target price on shares of Urogen Pharma in a report on Wednesday, July 15th.

Insider Buying and Selling at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the insider directly owned 119,763 shares in the company, valued at $4,790,520. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,222 shares of company stock worth $892,661 over the last three months. 4.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Urogen Pharma

A number of large investors have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP boosted its holdings in shares of Urogen Pharma by 6.1% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company's stock valued at $104,773,000 after acquiring an additional 257,564 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Urogen Pharma during the second quarter worth about $117,814,000. Morgan Stanley raised its holdings in Urogen Pharma by 1.4% during the fourth quarter. Morgan Stanley now owns 2,562,901 shares of the company's stock worth $60,023,000 after purchasing an additional 34,455 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in Urogen Pharma during the second quarter worth about $80,947,000. Finally, Soleus Capital Management L.P. acquired a new stake in Urogen Pharma in the second quarter valued at about $29,934,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

Urogen Pharma Stock Performance

Shares of Urogen Pharma stock opened at $46.86 on Friday. Urogen Pharma has a 1 year low of $15.86 and a 1 year high of $50.81. The company has a market capitalization of $2.29 billion, a P/E ratio of -23.67 and a beta of 1.57. The company's fifty day moving average is $40.51 and its two-hundred day moving average is $29.07.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. As a group, equities analysts expect that Urogen Pharma will post -0.2 earnings per share for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source